AAAAAA

   
Results: 1-10 |
Results: 10
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease
Authors: Potkin, SG Anand, R Fleming, K Alva, G Keator, D Carreon, D Messina, J Wu, JC Hartman, R Fallon, JH
Citation: Sg. Potkin et al., Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease, IN J NEUROP, 4(3), 2001, pp. 223-230
Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas
Authors: Cherpelis, BS Haddad, F Messina, J Cantor, AB Fitzmorris, K Reintgen, DS Fenske, NA Glass, LF
Citation: Bs. Cherpelis et al., Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas, J AM ACAD D, 44(5), 2001, pp. 762-766
Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome
Authors: Ichida, F Tsubata, S Bowles, KR Haneda, N Uese, K Miyawaki, T Dreyer, WJ Messina, J Li, H Bowles, NE Towbin, JA
Citation: F. Ichida et al., Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome, CIRCULATION, 103(9), 2001, pp. 1256-1263
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
Authors: Farlow, MR Hake, A Messina, J Hartman, R Veach, J Anand, R
Citation: Mr. Farlow et al., Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression, ARCH NEUROL, 58(3), 2001, pp. 417-422
An efficacy and safety analysis of Exelon (R) in Alzheimer's disease patients with concurrent vascular risk factors
Authors: Kumar, V Anand, R Messina, J Hartman, R Veach, J
Citation: V. Kumar et al., An efficacy and safety analysis of Exelon (R) in Alzheimer's disease patients with concurrent vascular risk factors, EUR J NEUR, 7(2), 2000, pp. 159-169
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
Authors: Farlow, M Anand, R Messina, J Hartman, R Veach, J
Citation: M. Farlow et al., A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease, EUR NEUROL, 44(4), 2000, pp. 236-241
Clinical relevance of molecular staging for melanoma - Comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma
Authors: Li, WG Stall, A Shivers, SC Lin, J Haddad, F Messina, J Glass, LF Lyman, G Reintgen, DS
Citation: Wg. Li et al., Clinical relevance of molecular staging for melanoma - Comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma, ANN SURG, 231(6), 2000, pp. 795-801
Cutaneous lymphatic drainage in patients with grossly involved nodal basins
Authors: Kamath, D Brobeil, A Stall, A Lyman, G Cruse, CW Glass, F Fenske, N Messina, J Berman, C Reintgen, D
Citation: D. Kamath et al., Cutaneous lymphatic drainage in patients with grossly involved nodal basins, ANN SURG O, 6(4), 1999, pp. 345-349
The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion
Authors: Haddad, FF Stall, A Messina, J Brobeil, A Ramnath, E Glass, LF Cruse, CW Berman, CG Reintgen, DS
Citation: Ff. Haddad et al., The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion, ANN SURG O, 6(2), 1999, pp. 144-149
Therapy of Alzheimer's disease with Exelon (TM): short- and long-term effects of a novel cholinesterase inhibitor
Authors: Anand, R Hartman, RD Messina, J
Citation: R. Anand et al., Therapy of Alzheimer's disease with Exelon (TM): short- and long-term effects of a novel cholinesterase inhibitor, ALZHEIM REP, 1, 1998, pp. S15-S16
Risultati: 1-10 |